E. Smit

A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments

A. D. de Langen, T. Hiltermann, A. van der Wekken, 2023, Cancer Treatment Reviews.

Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Edward S. Kim, H. Groen, E. Smit, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).

E. Smit, E. Thunnissen, M. D. den Bakker, 2019, Lung cancer.

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC).

H. Groen, E. Smit, R. Heist, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.

H. Groen, E. Smit, F. Schramel, 2019, Lung Cancer.

PHASE II ACTIVITY OF THE HSP90 INHIBITOR AUY922 IN PATIENTS WITH ALK-REARRANGED (ALK plus ) OR EGFR-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

L. Sequist, E. Felip, E. Garon, 2012 .